Motif Bio PLC Posters presented at IDWeek New Orleans
September 15 2016 - 1:01AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
15 September 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
.Motif Bio plc
("Motif Bio" or the "Company")
15 September 2016
POSTER PRESENTATION AT IDWEEK
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that it will be presenting two poster studies at IDWeek, October 26
to 30 in New Orleans, USA.
IDWeek is an annual gathering of 6,000 practitioners who are
members of the Infectious Disease Society of America (IDSA), the
Society for Healthcare Epidemiology of America (SHEA), the HIV
Medicine Association (HIVMA) and the Pediatric Infectious Diseases
Society (PIDS) and represents the largest gathering of practicing
professionals dedicated to the treatment, control and eradication
of infectious diseases.
Motif Bio will be presenting two posters at the session titled
'Antimicrobial Pharmacokinetics and Pharmacodynamics' on Saturday,
October 29, 2016 between 12.30 and 2.00 pm.
The first poster is titled 'The Use of PK/PD Systems Analyses to
Determine the Optimal Fixed Dosing Regimen of Iclaprim (ICL) for a
Phase III ABSSSI Clinical Trial'.
The second poster is titled 'A 2012-2014 Global Antimicrobial
Surveillance of Iclaprim Against Clinical Strains Causing
Hospital-Associated Bacterial Pneumonia (HABP) and Skin and Skin
Structure Infections (SSSI)'.
Following the conclusion of the conference, both poster
presentations will be made available on the Company website:
www.motifbio.com
For further information please contact:
Motif Bio plc info@motifbio.com
Richard Morgan (Chairman)
Graham Lumsden (Chief Executive
Officer)
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalized patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials with an intravenous formulation of
iclaprim, for the treatment of ABSSSI, which are expected to be
completed in 2017.
The ID Week partners:
The Infectious Diseases Society of America (IDSA) represents
physicians, scientists and other health care professionals who
specialize in infectious diseases. IDSA's purpose is to improve the
health of individuals, communities, and society by promoting
excellence in patient care, education, research, public health, and
prevention relating to infectious diseases. www.idsociety.org
The Society for Healthcare Epidemiology of America (SHEA) is a
professional society representing physicians and other healthcare
professionals around the world with expertise in healthcare
epidemiology and infection prevention and control. SHEA's mission
is to prevent and control healthcare-associated infections and
advance the field of healthcare epidemiology.
www.shea-online.org
The HIV Medicine Association (HIVMA) promotes quality in HIV
care by advocating policies and supporting programs that ensure a
comprehensive and humane response to the AIDS pandemic informed by
science and social justice. HIVMA represents the diversity of
medical subspecialties practicing HIV medicine-including internal
medicine, family practice, infectious diseases, oncology, and
obstetrics-gynecology. www.hivma.org
The Pediatric Infectious Diseases Society (PIDS) represents
professionals dedicated to the treatment, control and eradication
of infectious diseases affecting children. Membership includes
physicians and doctoral-level scientists who are involved in
clinical practice, research, teaching and/or administration.
www.pids.org
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKQDDCBKDCCD
(END) Dow Jones Newswires
September 15, 2016 02:01 ET (06:01 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024